DisperSol Technologies, LLC, a Georgetown, TX-based drug development technology company, raised over $10m in financing.
The round was led by Research Corporation Technologies, with participation from existing investors.
The company will use the funds to expand its drug formulation and GMP manufacturing capabilities for its partnerships with the pharmaceutical industry, to develop its own portfolio of proprietary drug products with improved bioavailability profiles.
Led by Gershon Yaniv, PhD, MBA, CEO, DisperSol Technologies uses an enabling processing technology called KinetiSol® to develop insoluble drug products in underserved areas. The company has completed numerous development programs with pharmaceutical companies to enhance the bioavailability of their most challenging molecules, and recently began developing its own portfolio of 505(b)(2) drug products.